{"name":"ELI LILLY AND CO","slug":"eli-lilly-and-co","ticker":"","exchange":"","domain":"elilillyand.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1000000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","revenue":1000000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1987-12-29","label":"Prozac first approved","drug":"Prozac","drugSlug":"fluoxetine","type":"approval","sentiment":"positive"},{"date":"2004-08-03","label":"Cymbalta first approved","drug":"Cymbalta","drugSlug":"duloxetine","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov016 first approved","drug":"Ly-Cov016","drugSlug":"etesevimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov555 first approved","drug":"Ly-Cov555","drugSlug":"bamlanivimab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Inluriyo first approved","drug":"Inluriyo","drugSlug":"imlunestrant","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Ebglyss first approved","drug":"Ebglyss","drugSlug":"lebrikizumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-01","label":"Inluriyo PHASE3 readout","drug":"Inluriyo","drugSlug":"imlunestrant","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":1000000000,"percentOfTotal":100,"drugCount":14,"colorKey":"oncology","drugs":[{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","indication":"Bipolar affective disorder, current episode depression","status":"marketed","revenue":1000000000},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","indication":"Chronic Musculoskeletal Pain","status":"marketed"},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","indication":"Major depressive disorder","status":"phase_3"},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","indication":"Schizophrenia maintenance treatment","status":"phase_3"},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","indication":"Major depressive disorder","status":"phase_3"},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","indication":"Alzheimer's disease (mild cognitive impairment and mild dementia stages)","status":"phase_3"},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","indication":"Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"phase_3"},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","indication":"Major depressive disorder","status":"phase_3"},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","indication":"Schizophrenia","status":"marketed"},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","indication":"Schizophrenia (maintenance treatment)","status":"phase_3"},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","indication":"Schizophrenia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":172,"colorKey":"immunology","drugs":[{"name":"Citrate-Free Mirikizumab","genericName":"Citrate-Free Mirikizumab","slug":"citrate-free-mirikizumab","indication":"Other","status":"phase_1"},{"name":"Glargine","genericName":"Glargine","slug":"glargine","indication":"Other","status":"marketed"},{"name":"LY686017","genericName":"LY686017","slug":"ly686017","indication":"Other","status":"phase_2"},{"name":"sPLA2 Inhibitor","genericName":"sPLA2 Inhibitor","slug":"spla2-inhibitor","indication":"Other","status":"phase_1"},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","indication":"Other","status":"phase_2"},{"name":"LY2228820","genericName":"LY2228820","slug":"ly2228820","indication":"Other","status":"phase_1"},{"name":"LY3041658","genericName":"LY3041658","slug":"ly3041658","indication":"Other","status":"phase_2"},{"name":"LY4064809 Test Formulation","genericName":"LY4064809 Test Formulation","slug":"ly4064809-test-formulation","indication":"Other","status":"phase_1"},{"name":"1121B","genericName":"1121B","slug":"1121b","indication":"Other","status":"phase_1"},{"name":"Degludec SC","genericName":"Degludec SC","slug":"degludec-sc","indication":"Other","status":"phase_1"},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","indication":"Other","status":"marketed"},{"name":"Eloralintide and Tirzepatide","genericName":"Eloralintide and Tirzepatide","slug":"eloralintide-and-tirzepatide","indication":"Other","status":"phase_1"},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","indication":"Other","status":"marketed"},{"name":"LY2393910","genericName":"LY2393910","slug":"ly2393910","indication":"Other","status":"phase_1"},{"name":"LY2584702 Test Formulation","genericName":"LY2584702 Test Formulation","slug":"ly2584702-test-formulation","indication":"Other","status":"phase_1"},{"name":"LY3200882","genericName":"LY3200882","slug":"ly3200882","indication":"Other","status":"phase_1"},{"name":"LY3295668 Erbumine","genericName":"LY3295668 Erbumine","slug":"ly3295668-erbumine","indication":"Other","status":"phase_1"},{"name":"LY3375880 IV","genericName":"LY3375880 IV","slug":"ly3375880-iv","indication":"Other","status":"phase_1"},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","indication":"Other","status":"phase_2"},{"name":"LY3847429","genericName":"LY3847429","slug":"ly3847429","indication":"Other","status":"phase_2"},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","indication":"Other","status":"phase_2"},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","indication":"Other","status":"phase_1"},{"name":"LY3981314","genericName":"LY3981314","slug":"ly3981314","indication":"Other","status":"phase_1"},{"name":"LY4052031","genericName":"LY4052031","slug":"ly4052031","indication":"Other","status":"phase_1"},{"name":"LY4088044","genericName":"LY4088044","slug":"ly4088044","indication":"Other","status":"phase_1"},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","indication":"Other","status":"phase_2"},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","indication":"Other","status":"phase_1"},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","indication":"Other","status":"phase_2"},{"name":"LY900014-U200","genericName":"LY900014-U200","slug":"ly900014-u200","indication":"Other","status":"phase_1"},{"name":"Lyumjev with 100% basal rate reduction","genericName":"Lyumjev with 100% basal rate reduction","slug":"lyumjev-with-100-basal-rate-reduction","indication":"Other","status":"phase_1"},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","indication":"Control arm in randomized controlled trials across multiple therapeutic areas","status":"marketed"},{"name":"US Approved Lantus","genericName":"US Approved Lantus","slug":"us-approved-lantus","indication":"Other","status":"phase_1"},{"name":"[14C]-LOXO-305","genericName":"[14C]-LOXO-305","slug":"14c-loxo-305","indication":"Other","status":"phase_1"},{"name":"[^14C]-LY2940680","genericName":"[^14C]-LY2940680","slug":"14c-ly2940680","indication":"Other","status":"phase_1"},{"name":"[¹⁴C]-LY3337641","genericName":"[¹⁴C]-LY3337641","slug":"c-ly3337641","indication":"Other","status":"phase_1"},{"name":"[¹⁴C]-LY3484356","genericName":"[¹⁴C]-LY3484356","slug":"c-ly3484356","indication":"Other","status":"phase_1"},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","indication":"Other","status":"marketed"},{"name":"opioid receptor kappa antagonist","genericName":"opioid receptor kappa antagonist","slug":"opioid-receptor-kappa-antagonist","indication":"Other","status":"phase_1"},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","indication":"Other","status":"marketed"},{"name":"¹³C₈-LY2835219","genericName":"¹³C₈-LY2835219","slug":"c-ly2835219","indication":"Other","status":"phase_1"},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","indication":"Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","status":"marketed"},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","indication":"Other","status":"phase_1"},{"name":"Axiron","genericName":"Axiron","slug":"axiron","indication":"Other","status":"marketed"},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","indication":"Other","status":"phase_2"},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","indication":"Other","status":"phase_1"},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","indication":"Other","status":"phase_3"},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","indication":"Other","status":"marketed"},{"name":"Evacetrapib Intravenous","genericName":"Evacetrapib Intravenous","slug":"evacetrapib-intravenous","indication":"Other","status":"phase_1"},{"name":"Glinides","genericName":"Glinides","slug":"glinides","indication":"Other","status":"phase_3"},{"name":"Humalog with 50% basal rate reduction","genericName":"Humalog with 50% basal rate reduction","slug":"humalog-with-50-basal-rate-reduction","indication":"Other","status":"phase_1"},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","indication":"Other","status":"marketed"},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","indication":"Other","status":"phase_2"},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","indication":"Other","status":"phase_2"},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","indication":"Other","status":"phase_1"},{"name":"LOXO-292","genericName":"LOXO-292","slug":"loxo-292","indication":"Other","status":"phase_1"},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","indication":"Other","status":"phase_1"},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","indication":"Huntington's disease","status":"phase_3"},{"name":"LY2157299","genericName":"LY2157299","slug":"ly2157299","indication":"Other","status":"phase_2"},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","indication":"Other","status":"phase_2"},{"name":"LY2334737","genericName":"LY2334737","slug":"ly2334737","indication":"Other","status":"phase_1"},{"name":"LY2405319","genericName":"LY2405319","slug":"ly2405319","indication":"Other","status":"phase_1"},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","indication":"Other","status":"phase_2"},{"name":"LY2484595","genericName":"LY2484595","slug":"ly2484595","indication":"Other","status":"phase_2"},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","indication":"Other","status":"phase_1"},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","indication":"Other","status":"phase_1"},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","indication":"Other","status":"phase_2"},{"name":"LY2608204 Reference","genericName":"LY2608204 Reference","slug":"ly2608204-reference","indication":"Other","status":"phase_1"},{"name":"LY2624803 - Capsules","genericName":"LY2624803 - Capsules","slug":"ly2624803-capsules","indication":"Other","status":"phase_1"},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","indication":"Other","status":"phase_1"},{"name":"LY2801653","genericName":"LY2801653","slug":"ly2801653","indication":"Other","status":"phase_1"},{"name":"LY2835219","genericName":"LY2835219","slug":"ly2835219","indication":"Other","status":"phase_1"},{"name":"LY2922083","genericName":"LY2922083","slug":"ly2922083","indication":"Other","status":"phase_1"},{"name":"LY2922470","genericName":"LY2922470","slug":"ly2922470","indication":"Other","status":"phase_1"},{"name":"LY2928057","genericName":"LY2928057","slug":"ly2928057","indication":"Other","status":"phase_1"},{"name":"LY3007113","genericName":"LY3007113","slug":"ly3007113","indication":"Other","status":"phase_1"},{"name":"LY3009385","genericName":"LY3009385","slug":"ly3009385","indication":"Other","status":"phase_1"},{"name":"LY3015014","genericName":"LY3015014","slug":"ly3015014","indication":"Other","status":"phase_2"},{"name":"LY3015014 SC","genericName":"LY3015014 SC","slug":"ly3015014-sc","indication":"Other","status":"phase_1"},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","indication":"Other","status":"phase_2"},{"name":"LY3023414 Test Fasted","genericName":"LY3023414 Test Fasted","slug":"ly3023414-test-fasted","indication":"Other","status":"phase_1"},{"name":"LY3025876","genericName":"LY3025876","slug":"ly3025876","indication":"Other","status":"phase_1"},{"name":"LY3045697","genericName":"LY3045697","slug":"ly3045697","indication":"Other","status":"phase_1"},{"name":"LY3050258","genericName":"LY3050258","slug":"ly3050258","indication":"Other","status":"phase_1"},{"name":"LY3079514","genericName":"LY3079514","slug":"ly3079514","indication":"Other","status":"phase_1"},{"name":"LY3090106","genericName":"LY3090106","slug":"ly3090106","indication":"Other","status":"phase_1"},{"name":"LY3090106 - IV","genericName":"LY3090106 - IV","slug":"ly3090106-iv","indication":"Other","status":"phase_1"},{"name":"LY3090106 - SQ","genericName":"LY3090106 - SQ","slug":"ly3090106-sq","indication":"Other","status":"phase_1"},{"name":"LY3108743 - Capsule","genericName":"LY3108743 - Capsule","slug":"ly3108743-capsule","indication":"Other","status":"phase_1"},{"name":"LY3127760","genericName":"LY3127760","slug":"ly3127760","indication":"Other","status":"phase_1"},{"name":"LY3164530","genericName":"LY3164530","slug":"ly3164530","indication":"Other","status":"phase_1"},{"name":"LY317615","genericName":"LY317615","slug":"ly317615","indication":"Other","status":"phase_2"},{"name":"LY3185643","genericName":"LY3185643","slug":"ly3185643","indication":"Other","status":"phase_1"},{"name":"LY3192767","genericName":"LY3192767","slug":"ly3192767","indication":"Other","status":"phase_1"},{"name":"LY3295668","genericName":"LY3295668","slug":"ly3295668","indication":"Other","status":"phase_1"},{"name":"LY3300054","genericName":"LY3300054","slug":"ly3300054","indication":"Other","status":"phase_1"},{"name":"LY3303560 - IV","genericName":"LY3303560 - IV","slug":"ly3303560-iv","indication":"Other","status":"phase_1"},{"name":"LY3316531","genericName":"LY3316531","slug":"ly3316531","indication":"Other","status":"phase_1"},{"name":"LY3316531 - IV","genericName":"LY3316531 - IV","slug":"ly3316531-iv","indication":"Other","status":"phase_1"},{"name":"LY3325656","genericName":"LY3325656","slug":"ly3325656","indication":"Other","status":"phase_1"},{"name":"LY333334","genericName":"LY333334","slug":"ly333334","indication":"Other","status":"phase_1"},{"name":"LY3361237 - IV","genericName":"LY3361237 - IV","slug":"ly3361237-iv","indication":"Other","status":"phase_1"},{"name":"LY3372689","genericName":"LY3372689","slug":"ly3372689","indication":"Other","status":"phase_2"},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","indication":"Other","status":"phase_2"},{"name":"LY3461767 - IV","genericName":"LY3461767 - IV","slug":"ly3461767-iv","indication":"Other","status":"phase_1"},{"name":"LY3461767 - SC","genericName":"LY3461767 - SC","slug":"ly3461767-sc","indication":"Other","status":"phase_1"},{"name":"LY3475766 - SC","genericName":"LY3475766 - SC","slug":"ly3475766-sc","indication":"Other","status":"phase_1"},{"name":"LY3478045","genericName":"LY3478045","slug":"ly3478045","indication":"Other","status":"phase_1"},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","indication":"Other","status":"phase_2"},{"name":"LY3532226","genericName":"LY3532226","slug":"ly3532226","indication":"Other","status":"phase_1"},{"name":"LY3537021","genericName":"LY3537021","slug":"ly3537021","indication":"Other","status":"phase_2"},{"name":"LY3541105","genericName":"LY3541105","slug":"ly3541105","indication":"Other","status":"phase_1"},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","indication":"Other","status":"phase_1"},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","indication":"Other","status":"phase_2"},{"name":"LY3866288","genericName":"LY3866288","slug":"ly3866288","indication":"Other","status":"phase_1"},{"name":"LY3871801","genericName":"LY3871801","slug":"ly3871801","indication":"Other","status":"phase_2"},{"name":"LY3876602","genericName":"LY3876602","slug":"ly3876602","indication":"Other","status":"phase_1"},{"name":"LY3971297","genericName":"LY3971297","slug":"ly3971297","indication":"Other","status":"phase_1"},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","indication":"Other","status":"phase_1"},{"name":"LY4064809 Reference Formulation","genericName":"LY4064809 Reference Formulation","slug":"ly4064809-reference-formulation","indication":"Other","status":"phase_1"},{"name":"LY4066708","genericName":"LY4066708","slug":"ly4066708","indication":"Other","status":"phase_1"},{"name":"LY4086940","genericName":"LY4086940","slug":"ly4086940","indication":"Other","status":"phase_1"},{"name":"LY4214835","genericName":"LY4214835","slug":"ly4214835","indication":"Other","status":"phase_1"},{"name":"LY4298445","genericName":"LY4298445","slug":"ly4298445","indication":"Other","status":"phase_1"},{"name":"LY4515100 via MAD","genericName":"LY4515100 via MAD","slug":"ly4515100-via-mad","indication":"Other","status":"phase_1"},{"name":"LY4584180","genericName":"LY4584180","slug":"ly4584180","indication":"Other","status":"phase_1"},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","indication":"Other","status":"phase_2"},{"name":"LY900014 U-200","genericName":"LY900014 U-200","slug":"ly900014-u-200","indication":"Other","status":"phase_1"},{"name":"LY900021","genericName":"LY900021","slug":"ly900021","indication":"Other","status":"phase_1"},{"name":"Lispro","genericName":"Lispro","slug":"lispro","indication":"Other","status":"marketed"},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","indication":"Other","status":"phase_1"},{"name":"Lyumjev with 50% basal rate reduction","genericName":"Lyumjev with 50% basal rate reduction","slug":"lyumjev-with-50-basal-rate-reduction","indication":"Other","status":"phase_1"},{"name":"Mirikizumab Test","genericName":"Mirikizumab Test","slug":"mirikizumab-test","indication":"Other","status":"phase_1"},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","indication":"Other","status":"phase_2"},{"name":"Pemetrexed - Phase 1","genericName":"Pemetrexed - Phase 1","slug":"pemetrexed-phase-1","indication":"Other","status":"phase_1"},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","indication":"Other","status":"phase_2"},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","indication":"Other","status":"phase_3"},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","indication":"Control arm in phase 3 clinical trials (specific indication unknown)","status":"phase_3"},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","indication":"Control arm in phase 3 clinical trials of abemaciclib","status":"phase_3"},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","indication":"Clinical trial control comparator (not a therapeutic indication)","status":"marketed"},{"name":"Platinol","genericName":"Platinol","slug":"platinol","indication":"Other","status":"phase_1"},{"name":"Prophylactic Loperamide","genericName":"Prophylactic Loperamide","slug":"prophylactic-loperamide","indication":"Other","status":"phase_2"},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","indication":"Other","status":"marketed"},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","indication":"Other","status":"phase_1"},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","indication":"Other","status":"phase_2"},{"name":"SC Glucagon","genericName":"SC Glucagon","slug":"sc-glucagon","indication":"Other","status":"phase_2"},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","indication":"Paget's disease of bone","status":"marketed"},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","indication":"Other","status":"phase_2"},{"name":"TT223","genericName":"TT223","slug":"tt223","indication":"Other","status":"phase_1"},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","indication":"Other","status":"marketed"},{"name":"Tadalafil- Tablet or Oral suspension","genericName":"Tadalafil- Tablet or Oral suspension","slug":"tadalafil-tablet-or-oral-suspension","indication":"Other","status":"phase_1"},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","indication":"Other","status":"phase_3"},{"name":"Zolpidem - Tablets","genericName":"Zolpidem - Tablets","slug":"zolpidem-tablets","indication":"Other","status":"phase_1"},{"name":"[14C]-LY3154207","genericName":"[14C]-LY3154207","slug":"14c-ly3154207","indication":"Other","status":"phase_1"},{"name":"[14C]-LY3214996","genericName":"[14C]-LY3214996","slug":"14c-ly3214996","indication":"Other","status":"phase_1"},{"name":"[14C]-LY3502970","genericName":"[14C]-LY3502970","slug":"14c-ly3502970","indication":"Other","status":"phase_1"},{"name":"[14C]-LY3549492","genericName":"[14C]-LY3549492","slug":"14c-ly3549492","indication":"Other","status":"phase_1"},{"name":"[14C]-Selpercatinib","genericName":"[14C]-Selpercatinib","slug":"14c-selpercatinib","indication":"Other","status":"phase_1"},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","indication":"Other","status":"phase_1"},{"name":"[^14C]-LY2835219","genericName":"[^14C]-LY2835219","slug":"14c-ly2835219","indication":"Other","status":"phase_1"},{"name":"[¹⁴C]-LOXO-783","genericName":"[¹⁴C]-LOXO-783","slug":"c-loxo-783","indication":"Other","status":"phase_1"},{"name":"[¹⁴C]-LY3023414","genericName":"[¹⁴C]-LY3023414","slug":"c-ly3023414","indication":"Other","status":"phase_1"},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","indication":"Other","status":"phase_2"},{"name":"multi-vitamins","genericName":"multi-vitamins","slug":"multi-vitamins","indication":"Other","status":"phase_1"},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","indication":"Erectile dysfunction","status":"phase_3"},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","indication":"Other","status":"marketed"},{"name":"rGlucagon","genericName":"rGlucagon","slug":"rglucagon","indication":"Other","status":"phase_1"},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","indication":"Postmenopausal osteoporosis prevention and treatment","status":"marketed"},{"name":"tadalafil as needed [T(PRN)]","genericName":"tadalafil as needed [T(PRN)]","slug":"tadalafil-as-needed-t-prn","indication":"Other","status":"phase_3"},{"name":"teriparatide 20 micrograms/day subcutaneous","genericName":"teriparatide 20 micrograms/day subcutaneous","slug":"teriparatide-20-micrograms-day-subcutaneous","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":60,"colorKey":"infectious","drugs":[{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"AM0010","genericName":"AM0010","slug":"am0010","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","indication":"Type 1 diabetes","status":"phase_2"},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","indication":"Severe hypoglycemia in patients with diabetes mellitus","status":"phase_3"},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"OAMs","genericName":"OAMs","slug":"oams","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","indication":"Treatment of diabetes mellitus","status":"phase_3"},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","indication":"Type 1 diabetes","status":"phase_3"},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"cardiovascular","drugs":[{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","indication":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","status":"marketed"},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","indication":"Small cell lung cancer (SCLC)","status":"phase_3"},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"marketed"},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","indication":"FGFR-altered solid tumors (Phase 2 development)","status":"phase_2"},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","indication":"Metastatic non-small cell lung cancer (in combination with docetaxel)","status":"phase_3"},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","indication":"Non-small cell lung cancer, gastric cancer, and other solid tumors","status":"phase_3"},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","indication":"Metastatic gastric cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"rare","drugs":[{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","indication":"Moderate to severe plaque psoriasis","status":"marketed"},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","indication":"Moderately to severely active ulcerative colitis","status":"marketed"},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","indication":"Acute myocardial infarction","status":"phase_3"},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","indication":"Eczema","status":"phase_3"},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","indication":"Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","status":"marketed"},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"respiratory","drugs":[{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","indication":"Acute coronary syndrome","status":"phase_2"},{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","indication":"Hypertension","status":"marketed"},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","indication":"Osteoporosis prevention and treatment in postmenopausal women","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","indication":"COVID-19","status":"marketed"},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","indication":"COVID-19","status":"discontinued"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","indication":"Moderate-to-severe atopic dermatitis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","indication":"Moderate-to-severe atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","phase":"marketed","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown.","indications":["Bipolar affective disorder, current episode depression","Bulimia nervosa","Depressive disorder","Major depressive disorder","Obsessive-compulsive disorder"],"catalyst":""},{"name":"Citrate-Free Mirikizumab","genericName":"Citrate-Free Mirikizumab","slug":"citrate-free-mirikizumab","phase":"phase_1","mechanism":"Mirikizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor.","indications":[],"catalyst":""},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","phase":"marketed","mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms.","indications":["Chronic Musculoskeletal Pain","Diabetic peripheral neuropathy","Female stress incontinence","Fibromyalgia","Generalized anxiety disorder"],"catalyst":""},{"name":"Glargine","genericName":"Glargine","slug":"glargine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","phase":"marketed","mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading.","indications":["ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy"],"catalyst":""},{"name":"LY686017","genericName":"LY686017","slug":"ly686017","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"sPLA2 Inhibitor","genericName":"sPLA2 Inhibitor","slug":"spla2-inhibitor","phase":"phase_1","mechanism":"Inhibits secretory phospholipase A2 (sPLA2) enzymes to reduce inflammatory mediator production.","indications":[],"catalyst":""},{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","phase":"marketed","mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin.","indications":["Moderate-to-severe atopic dermatitis"],"catalyst":""},{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","phase":"phase_3","mechanism":"Human insulin delivered via inhalation powder replaces or supplements endogenous insulin to regulate blood glucose by promoting glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2228820","genericName":"LY2228820","slug":"ly2228820","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3041658","genericName":"LY3041658","slug":"ly3041658","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","phase":"phase_3","mechanism":"LY3537031 is a GLP-1 and GIP receptor dual agonist that activates both incretin pathways to improve glucose control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","phase":"phase_3","mechanism":"LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY4064809 Test Formulation","genericName":"LY4064809 Test Formulation","slug":"ly4064809-test-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"1121B","genericName":"1121B","slug":"1121b","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","phase":"phase_2","mechanism":"ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.","indications":["Acute coronary syndrome","Myocardial infarction"],"catalyst":""},{"name":"AM0010","genericName":"AM0010","slug":"am0010","phase":"phase_2","mechanism":"AM0010 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","phase":"marketed","mechanism":"Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.","indications":["Hypertension","Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","phase":"phase_2","mechanism":"Human insulin analogs mimic the action of the body's natural insulin, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","phase":"marketed","mechanism":"Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial glycerol-3-phosphate dehydrogenase.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Degludec SC","genericName":"Degludec SC","slug":"degludec-sc","phase":"phase_1","mechanism":"Binds to insulin receptors to facilitate glucose uptake and regulate blood sugar levels with ultra-long duration of action.","indications":[],"catalyst":""},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","phase":"phase_3","mechanism":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric cancer","Head and neck cancer"],"catalyst":""},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","phase":"phase_3","mechanism":"Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Eloralintide and Tirzepatide","genericName":"Eloralintide and Tirzepatide","slug":"eloralintide-and-tirzepatide","phase":"phase_1","mechanism":"Combination therapy mechanism not fully disclosed; tirzepatide is a dual GIP/GLP-1 receptor agonist, eloralintide mechanism unknown.","indications":[],"catalyst":""},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes mellitus","Diagnostic aid in radiologic examination of the gastrointestinal tract"],"catalyst":""},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","phase":"phase_3","mechanism":"Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","phase":"marketed","mechanism":"Huminsulin Regular is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","phase":"phase_3","mechanism":"Insulin Aspart 6 Day is a long-acting basal insulin analog designed to provide extended glucose control with a 6-day duration of action.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","phase":"marketed","mechanism":"Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","phase":"marketed","mechanism":"Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia maintenance treatment","Bipolar I disorder maintenance treatment"],"catalyst":""},{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","phase":"marketed","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","phase":"phase_2","mechanism":"Selective Bruton's tyrosine kinase (BTK) inhibitor","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","phase":"phase_3","mechanism":"LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.","indications":["Major depressive disorder","Circadian rhythm sleep disorders"],"catalyst":""},{"name":"LY2393910","genericName":"LY2393910","slug":"ly2393910","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2584702 Test Formulation","genericName":"LY2584702 Test Formulation","slug":"ly2584702-test-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","phase":"phase_3","mechanism":"LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","phase":"phase_3","mechanism":"LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY3200882","genericName":"LY3200882","slug":"ly3200882","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3295668 Erbumine","genericName":"LY3295668 Erbumine","slug":"ly3295668-erbumine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3375880 IV","genericName":"LY3375880 IV","slug":"ly3375880-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","phase":"phase_3","mechanism":"LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3847429","genericName":"LY3847429","slug":"ly3847429","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3981314","genericName":"LY3981314","slug":"ly3981314","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4052031","genericName":"LY4052031","slug":"ly4052031","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4088044","genericName":"LY4088044","slug":"ly4088044","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","phase":"phase_3","mechanism":"LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.","indications":["Alzheimer's disease (mild cognitive impairment and mild dementia stages)"],"catalyst":""},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY900014-U200","genericName":"LY900014-U200","slug":"ly900014-u200","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","phase":"marketed","mechanism":"Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"Lyumjev with 100% basal rate reduction","genericName":"Lyumjev with 100% basal rate reduction","slug":"lyumjev-with-100-basal-rate-reduction","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","phase":"phase_3","mechanism":"Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","phase":"marketed","mechanism":"Interleukin-23 subunit alpha","indications":["Moderately to severely active ulcerative colitis"],"catalyst":""},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","phase":"phase_3","mechanism":"This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","indications":["Attention-Deficit/Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","phase":"marketed","mechanism":"Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous healing mechanisms independent of pharmacological action.","indications":["Control arm in randomized controlled trials across multiple therapeutic areas"],"catalyst":""},{"name":"US Approved Lantus","genericName":"US Approved Lantus","slug":"us-approved-lantus","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-LOXO-305","genericName":"[14C]-LOXO-305","slug":"14c-loxo-305","phase":"phase_1","mechanism":"Radiolabeled tracer form of pirtobrutinib, a BTK inhibitor, used to study drug metabolism and pharmacokinetics.","indications":[],"catalyst":""},{"name":"[^14C]-LY2940680","genericName":"[^14C]-LY2940680","slug":"14c-ly2940680","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[¹⁴C]-LY3337641","genericName":"[¹⁴C]-LY3337641","slug":"c-ly3337641","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[¹⁴C]-LY3484356","genericName":"[¹⁴C]-LY3484356","slug":"c-ly3484356","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"opioid receptor kappa antagonist","genericName":"opioid receptor kappa antagonist","slug":"opioid-receptor-kappa-antagonist","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"¹³C₈-LY2835219","genericName":"¹³C₈-LY2835219","slug":"c-ly2835219","phase":"phase_1","mechanism":"Inhibits cyclin-dependent kinases 4 and 6, blocking cell cycle progression in cancer cells.","indications":[],"catalyst":""},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","phase":"phase_1","mechanism":"Topoisomerase I inhibitor","indications":["Non-small cell lung cancer","Mesothelioma"],"catalyst":""},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","phase":"marketed","mechanism":"Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis.","indications":["Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","Hypoparathyroidism","Vitamin D-dependent rickets","Osteoporosis"],"catalyst":""},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","phase":"phase_2","mechanism":"Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death.","indications":["Non-small cell lung cancer","Small cell lung cancer","Ovarian cancer","Bladder cancer","Head and neck cancer"],"catalyst":""},{"name":"Axiron","genericName":"Axiron","slug":"axiron","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","phase":"phase_3","mechanism":"BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.","indications":["Small cell lung cancer (SCLC)","Melanoma"],"catalyst":""},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","phase":"marketed","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with chemotherapy)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","phase":"phase_3","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","indications":["Acute myocardial infarction","Ischemic stroke prevention","Transient ischemic attack (TIA) prevention","Coronary artery disease","Mild to moderate pain"],"catalyst":""},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","phase":"marketed","mechanism":"Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus","Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"],"catalyst":""},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Squamous cell carcinoma of the head and neck","Non-small cell lung cancer"],"catalyst":""},{"name":"Evacetrapib Intravenous","genericName":"Evacetrapib Intravenous","slug":"evacetrapib-intravenous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glinides","genericName":"Glinides","slug":"glinides","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","phase":"phase_3","mechanism":"Humalog Mix 50 is a combination insulin therapy that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Humalog with 50% basal rate reduction","genericName":"Humalog with 50% basal rate reduction","slug":"humalog-with-50-basal-rate-reduction","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","phase":"marketed","mechanism":"Human Regular U-500 Insulin is a concentrated insulin formulation that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (particularly in insulin-resistant patients requiring high doses)"],"catalyst":""},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","phase":"marketed","mechanism":"Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","phase":"marketed","mechanism":"Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (when oral agents are insufficient)"],"catalyst":""},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","phase":"marketed","mechanism":"This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","phase":"marketed","mechanism":"Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","phase":"phase_3","mechanism":"Insulin Lispro 6 Day is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","phase":"marketed","mechanism":"Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","phase":"marketed","mechanism":"Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","phase":"marketed","mechanism":"Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","phase":"marketed","mechanism":"Insulin lispro low mix is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiological insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","phase":"phase_3","mechanism":"Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","phase":"phase_3","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"LOXO-292","genericName":"LOXO-292","slug":"loxo-292","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","phase":"phase_3","mechanism":"LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.","indications":["Huntington's disease"],"catalyst":""},{"name":"LY2157299","genericName":"LY2157299","slug":"ly2157299","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","phase":"phase_3","mechanism":"LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","phase":"phase_3","mechanism":"LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"LY2334737","genericName":"LY2334737","slug":"ly2334737","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2405319","genericName":"LY2405319","slug":"ly2405319","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2484595","genericName":"LY2484595","slug":"ly2484595","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2608204 Reference","genericName":"LY2608204 Reference","slug":"ly2608204-reference","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2624803 - Capsules","genericName":"LY2624803 - Capsules","slug":"ly2624803-capsules","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2801653","genericName":"LY2801653","slug":"ly2801653","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2835219","genericName":"LY2835219","slug":"ly2835219","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2922083","genericName":"LY2922083","slug":"ly2922083","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2922470","genericName":"LY2922470","slug":"ly2922470","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2928057","genericName":"LY2928057","slug":"ly2928057","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3007113","genericName":"LY3007113","slug":"ly3007113","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3009385","genericName":"LY3009385","slug":"ly3009385","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3015014","genericName":"LY3015014","slug":"ly3015014","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3015014 SC","genericName":"LY3015014 SC","slug":"ly3015014-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3023414 Test Fasted","genericName":"LY3023414 Test Fasted","slug":"ly3023414-test-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3025876","genericName":"LY3025876","slug":"ly3025876","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3045697","genericName":"LY3045697","slug":"ly3045697","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3050258","genericName":"LY3050258","slug":"ly3050258","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3079514","genericName":"LY3079514","slug":"ly3079514","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3090106","genericName":"LY3090106","slug":"ly3090106","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3090106 - IV","genericName":"LY3090106 - IV","slug":"ly3090106-iv","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"LY3090106 - SQ","genericName":"LY3090106 - SQ","slug":"ly3090106-sq","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"LY3108743 - Capsule","genericName":"LY3108743 - Capsule","slug":"ly3108743-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3127760","genericName":"LY3127760","slug":"ly3127760","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3164530","genericName":"LY3164530","slug":"ly3164530","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY317615","genericName":"LY317615","slug":"ly317615","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3185643","genericName":"LY3185643","slug":"ly3185643","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3192767","genericName":"LY3192767","slug":"ly3192767","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3295668","genericName":"LY3295668","slug":"ly3295668","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3300054","genericName":"LY3300054","slug":"ly3300054","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3303560 - IV","genericName":"LY3303560 - IV","slug":"ly3303560-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3316531","genericName":"LY3316531","slug":"ly3316531","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3316531 - IV","genericName":"LY3316531 - IV","slug":"ly3316531-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3325656","genericName":"LY3325656","slug":"ly3325656","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY333334","genericName":"LY333334","slug":"ly333334","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3361237 - IV","genericName":"LY3361237 - IV","slug":"ly3361237-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3372689","genericName":"LY3372689","slug":"ly3372689","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3461767 - IV","genericName":"LY3461767 - IV","slug":"ly3461767-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3461767 - SC","genericName":"LY3461767 - SC","slug":"ly3461767-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3475766 - SC","genericName":"LY3475766 - SC","slug":"ly3475766-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3478045","genericName":"LY3478045","slug":"ly3478045","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3532226","genericName":"LY3532226","slug":"ly3532226","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","phase":"phase_3","mechanism":"LY353381 is a selective estrogen receptor modulator (SERM) that acts as a partial agonist at estrogen receptors to provide bone-protective and cardiovascular benefits without stimulating breast or endometrial tissue.","indications":["Osteoporosis prevention and treatment in postmenopausal women","Cardiovascular risk reduction in postmenopausal women"],"catalyst":""},{"name":"LY3537021","genericName":"LY3537021","slug":"ly3537021","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3541105","genericName":"LY3541105","slug":"ly3541105","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","phase":"phase_3","mechanism":"LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","phase":"phase_2","mechanism":"LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).","indications":["Metastatic non-small cell lung cancer","Metastatic triple-negative breast cancer"],"catalyst":""},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","phase":"phase_2","mechanism":"LY3838915 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3866288","genericName":"LY3866288","slug":"ly3866288","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3871801","genericName":"LY3871801","slug":"ly3871801","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3876602","genericName":"LY3876602","slug":"ly3876602","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3971297","genericName":"LY3971297","slug":"ly3971297","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4064809 Reference Formulation","genericName":"LY4064809 Reference Formulation","slug":"ly4064809-reference-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","phase":"phase_2","mechanism":"LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","indications":["FGFR-altered solid tumors (Phase 2 development)"],"catalyst":""},{"name":"LY4066708","genericName":"LY4066708","slug":"ly4066708","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4086940","genericName":"LY4086940","slug":"ly4086940","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4214835","genericName":"LY4214835","slug":"ly4214835","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4298445","genericName":"LY4298445","slug":"ly4298445","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4515100 via MAD","genericName":"LY4515100 via MAD","slug":"ly4515100-via-mad","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4584180","genericName":"LY4584180","slug":"ly4584180","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","phase":"phase_3","mechanism":"LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","phase":"phase_3","mechanism":"LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY900014 U-200","genericName":"LY900014 U-200","slug":"ly900014-u-200","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY900021","genericName":"LY900021","slug":"ly900021","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","phase":"phase_3","mechanism":"Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.","indications":["Moderate-to-severe atopic dermatitis","Uncontrolled asthma with type 2 inflammation"],"catalyst":""},{"name":"Lispro","genericName":"Lispro","slug":"lispro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","phase":"marketed","mechanism":"Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","phase":"marketed","mechanism":"Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","phase":"marketed","mechanism":"Lispro Mix 50/50 is a combination insulin that provides both rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","phase":"marketed","mechanism":"Lispro mix 75/25 is a combination insulin that provides rapid-acting insulin coverage for mealtime glucose spikes plus intermediate-acting basal insulin for baseline glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","phase":"discontinued","mechanism":"Ly-Cov555 works by binding to the SARS-CoV-2 virus and preventing it from entering host cells.","indications":["COVID-19"],"catalyst":""},{"name":"Lyumjev with 50% basal rate reduction","genericName":"Lyumjev with 50% basal rate reduction","slug":"lyumjev-with-50-basal-rate-reduction","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mirikizumab Test","genericName":"Mirikizumab Test","slug":"mirikizumab-test","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","phase":"marketed","mechanism":"NPH insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"OAMs","genericName":"OAMs","slug":"oams","phase":"phase_3","mechanism":"OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Agitation associated with schizophrenia or bipolar disorder","Adjunctive treatment of major depressive disorder"],"catalyst":""},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","phase":"phase_3","mechanism":"Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults","Narcolepsy"],"catalyst":""},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Gastric adenocarcinoma"],"catalyst":""},{"name":"Pemetrexed - Phase 1","genericName":"Pemetrexed - Phase 1","slug":"pemetrexed-phase-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","indications":["Control arm in phase 3 clinical trials (specific indication unknown)"],"catalyst":""},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in phase 3 clinical trials of abemaciclib"],"catalyst":""},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","phase":"marketed","mechanism":"Placebo produces no pharmacological effect and works entirely through the placebo effect, a psychobiological response to the expectation of treatment.","indications":["Clinical trial control comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Platinol","genericName":"Platinol","slug":"platinol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood sugar levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Prophylactic Loperamide","genericName":"Prophylactic Loperamide","slug":"prophylactic-loperamide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenesis and vascular growth.","indications":["Metastatic non-small cell lung cancer (in combination with docetaxel)","Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy)","Metastatic colorectal cancer (in combination with FOLFIRI)","Hepatocellular carcinoma (in combination with atezolizumab)"],"catalyst":""},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Non-small cell lung cancer, gastric cancer, and other solid tumors"],"catalyst":""},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","indications":["Treatment of schizophrenia","Treatment of bipolar disorder"],"catalyst":""},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"SC Glucagon","genericName":"SC Glucagon","slug":"sc-glucagon","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","phase":"marketed","mechanism":"Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels.","indications":["Paget's disease of bone","Hypercalcemia of malignancy","Osteoporosis in postmenopausal women","Acute bone loss following immobilization"],"catalyst":""},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","phase":"phase_3","mechanism":"Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","phase":"phase_3","mechanism":"Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.","indications":["Growth hormone deficiency in children","Growth hormone deficiency in adults","Short stature associated with Turner syndrome","Chronic kidney disease-related growth failure"],"catalyst":""},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","phase":"phase_3","mechanism":"Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.","indications":["Type 2 diabetes","Polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TT223","genericName":"TT223","slug":"tt223","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tadalafil- Tablet or Oral suspension","genericName":"Tadalafil- Tablet or Oral suspension","slug":"tadalafil-tablet-or-oral-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","phase":"phase_3","mechanism":"Topical corticosteroids reduce inflammation by suppressing the immune system's response to perceived threats.","indications":["Eczema","Psoriasis","Dermatitis"],"catalyst":""},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","phase":"marketed","mechanism":"Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","Rheumatoid arthritis and other joint disorders","Respiratory conditions (asthma, COPD)","Adrenocortical insufficiency","Systemic lupus erythematosus and other autoimmune diseases"],"catalyst":""},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","phase":"phase_3","mechanism":"Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas.","indications":["Treatment of diabetes mellitus"],"catalyst":""},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zolpidem - Tablets","genericName":"Zolpidem - Tablets","slug":"zolpidem-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-LY3154207","genericName":"[14C]-LY3154207","slug":"14c-ly3154207","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-LY3214996","genericName":"[14C]-LY3214996","slug":"14c-ly3214996","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-LY3502970","genericName":"[14C]-LY3502970","slug":"14c-ly3502970","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-LY3549492","genericName":"[14C]-LY3549492","slug":"14c-ly3549492","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-Selpercatinib","genericName":"[14C]-Selpercatinib","slug":"14c-selpercatinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[^14C]-LY2835219","genericName":"[^14C]-LY2835219","slug":"14c-ly2835219","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[¹⁴C]-LOXO-783","genericName":"[¹⁴C]-LOXO-783","slug":"c-loxo-783","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[¹⁴C]-LY3023414","genericName":"[¹⁴C]-LY3023414","slug":"c-ly3023414","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","phase":"phase_3","mechanism":"cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","phase":"phase_3","mechanism":"Injected insulin works by mimicking the action of the body's natural insulin hormone, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","phase":"marketed","mechanism":"Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"multi-vitamins","genericName":"multi-vitamins","slug":"multi-vitamins","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","phase":"phase_3","mechanism":"Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Acute agitation associated with schizophrenia or bipolar disorder","Treatment-resistant depression (in combination with fluoxetine)"],"catalyst":""},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","phase":"phase_3","mechanism":"Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, which works by increasing blood flow to the penis to treat erectile dysfunction.","indications":["Erectile dysfunction"],"catalyst":""},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"rGlucagon","genericName":"rGlucagon","slug":"rglucagon","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","phase":"marketed","mechanism":"This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.","indications":["Postmenopausal osteoporosis prevention and treatment"],"catalyst":""},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Metastatic gastric cancer","Non-small cell lung cancer","Advanced or metastatic breast cancer"],"catalyst":""},{"name":"tadalafil as needed [T(PRN)]","genericName":"tadalafil as needed [T(PRN)]","slug":"tadalafil-as-needed-t-prn","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"teriparatide 20 micrograms/day subcutaneous","genericName":"teriparatide 20 micrograms/day subcutaneous","slug":"teriparatide-20-micrograms-day-subcutaneous","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":280,"phaseCounts":{"marketed":58,"phase_1":110,"phase_2":41,"phase_3":70,"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}